Back to Stakeholders
Categories

1 domain / 2 areas / 3 specializations

Research, Drug Development & Manufacturing
Clinical Trial InfrastructurePatient Recruitment & Retention PlatformsSite Networks & SMOsSpecialized Trial Services
Research, Drug Development & Manufacturing

CenExel

Data updated

CenExel JBR - 650 East 4500 South Suite #100, Salt Lake City, UT 84107, United States

U.S. site network with a dedicated psychedelics capability page, private dosing rooms, facilitator training, specialty assessment support, and participant enrollment infrastructure.

Clinical Trial Infrastructure Snapshot

Site Networks & SMOs

Service Model

Site Network / SMO

Service Coverage

1 country

Psychedelic Experience

Verified Psychedelic Trial Experience

Last Source Check

Jun 18, 2026

Public Sources

4

Lifecycle Coverage

Feasibility & Protocol DesignStudy Startup & Site ActivationRecruitment & RetentionTrial Operations & MonitoringData Management & Biostatistics

Service Coverage Countries

United States

Phase Coverage

Phase IPhase IIPhase III

Capabilities

Site Network AccessPatient Recruitment MediaBiometrics / StatisticsMedical Imaging / Endpoints

Research Update

Public-source profile available

Last checked Jun 18, 2026 across 4 sources.

Search Finding

Dedicated psychedelics capability page; facilitator training, private dosing rooms, EEG/imaging consultation, and diverse enrollment strategy.

Primary Service Link

Service Notes

Strong site-network fit. Center-level mapping should be handled separately because the research supports the U.S. network but not every center's psychedelic activity.

Linked Stakeholders

No linked stakeholders yet.

Linked Trials

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Recruiting

A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Active not recruiting

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (EXTEND)

Enrolling by invitation

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Active not recruiting

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Active not recruiting

A Study of a Psilocybin Analog (CYB003) in Humans With Major Depressive Disorder (APPROACH)

Recruiting

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Active not recruiting

Psilocybin for Major Depressive Disorder (MDD) (uAspire)

Active not recruiting

BPL-003 Efficacy and Safety in Treatment Resistant Depression

Completed

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Completed

Source Evidence

CenExel — Expertise

https://cenexelresearch.com/expertise-old/

CenExel — Home

https://cenexelresearch.com/

CenExel JBR - Contact

https://cenexelresearch.com/jbr/contact/

CenExel psychedelics expertise

https://cenexelresearch.com/our-expertise/

Quick Facts

HQ
CenExel JBR - 650 East 4500 South Suite #100, Salt Lake City, UT 84107, United States
Website
Visit